Nolotil or metamizole: common questions, limits and precautions
Let's be straightforward. You have probably heard about Nolotil many times. In some homes it is mentioned almost as if it were "just another" common painkiller. But here it is worth slowing down a little.
What Nolotil or metamizole is and why it raises so many questions
Metamizole is the active substance. Nolotil is one of its brand names. The official SmPC describes it as a non-narcotic pyrazolone painkiller with analgesic, antipyretic and antispasmodic effects, and also notes that its mechanism of action is not fully understood.
That already explains part of the confusion. Many people mentally file it under "medicines for pain and fever", but metamizole doesn't fit neatly into a simplified view.
What situations it is really used for
According to the official SmPC for Nolotil 575 mg capsules, its indications are not "any pain" or "any fever". It is approved for acute moderate or intense post-operative or post-traumatic pain, colic-type pain, tumour-related pain and high fever that does not respond to other measures, including first-line antipyretics.
This point is important because it changes how the medicine should be read.
Why it should not be treated as a painkiller "without nuances"
The main reason is well known: metamizole can cause agranulocytosis, a serious and potentially fatal haematological adverse reaction. Both AEMPS and the EMA note that it can appear at any moment during treatment or shortly after stopping it.
AEMPS reported in 2023 that there were no new findings that would change the already-known safety profile and noted that the incidence of agranulocytosis among people starting metamizole was very low, in the range of 1 to 10 cases per million users. The European review closed by the European Commission's final decision of 22 November 2024 concluded that the benefits of metamizole continue to outweigh its risks, but reinforced the safety information to facilitate early detection of this side effect.
Warning signs and profiles where caution should be heightened
Official information stresses that the patient must stop treatment and seek immediate medical attention if symptoms suggestive of agranulocytosis appear, such as fever, chills, sore throat or painful lesions on mucous membranes.
Nor is it a medicine for everyone. The SmPC lists contraindications and profiles of special caution: history of agranulocytosis induced by metamizole or by other pyrazolones/pyrazolidines, bone marrow disorders or haematopoietic diseases, and patients with analgesic-induced asthma syndrome or intolerance to other painkillers of the urticaria-angio-oedema type.
Common questions that come up at the pharmacy
Are Nolotil and metamizole the same?
Not exactly. Metamizole is the active substance and Nolotil is a brand name.
Does it work for any pain or any fever?
It's not worth framing it that way. The SmPC places it in specific indications and, at least in the oral 575 mg capsule presentation consulted in CIMA, short-term use is also emphasised.
If I've taken it other times without problems, can I be reassured?
Not entirely. Agranulocytosis can appear even in people who had previously taken metamizole without complications.
Is it better or stronger than other common painkillers?
That's not a useful way to think about it. Rather than "better or worse", it makes more sense to think in terms of "different context, different profile and different cautions".
You may also be interested in reading about paracetamol and Adiro 100.
